Galapagos Hit By Atopic Dermatitis Drug Fail
End For IL-7C Inhibitor Partnered With MorphoSys And Novartis
Executive Summary
The fundamentals for Galapagos are sound despite the failure of MOR106 for atopic dermatitis and two trials of filgotinib missing their primary endpoints for Sjögren’s syndrome and lupus.
You may also be interested in...
AbbVie’s Post-Humira Strategy Continues Taking Shape With Rinvoq Approval
AbbVie now has both of its Humira successors approved in the US, following April’s Skyrizi approval for psoriasis. But Rinvoq faces stiff competition both within the JAK1 class and in rheumatoid arthritis generally.
$5bn Galapagos Deal Won’t Be Last For Gilead, Says O’Day
Handing over $5bn to Galapagos for access to several shots on the inflammation/fibrosis goal, Gilead Sciences CEO Daniel O’Day is still on the prowl for more.
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.